100 results about "Viral glycoprotein" patented technology

This invention relates to one anti-rabies virus antigen gold immune analysis test agent board and its process method, which comprises the following steps: paving glass fiber paper and aqua fortis fiber film on the underlay film of polyethylene board and polychloroethylene underlay film; covering the film onto the test line and comparison line; the test line is added with gold detector ester polymer film; the comparison line side is added with water absorptive pad; the test line is to cover the virus protein. This invention process method is to cover virus protein analysis film by glue gold label rabbit anti-virus IgG multi-clone antigen to process gold detection combination pad.

The invention belongs to the technical field of biology, and particularly relates to screening and identification of antigen epitope polypeptides. The invention discloses screening, identification and application of a series of rabies virus glycoprotein and nucleoprotein antigen epitope polypeptides. The rabies virus glycoprotein and nucleoprotein are predicted by biological information means to obtain the candidate epitope polypeptides; and a lymphopoiesis experiment, ELISPOT experiment and a stream-type cell method are utilized to carry out in-vitro experimental verification on the subsequent epitope polypeptides to obtain the four rabies virus protein antigen epitope polypeptides. The invention is characterized in that the antigen epitope polypeptides respectively comprise a Th epitope and a CTL epitope, can stimulate the lymphopoiesis of the vaccine-immunized mouse in vitro and induce the cells to secrete related cell factors, and have the functions of killing virus-infected cells and stimulating the generation of the antibody. The invention can be used for developing rabies virus epitope vaccines and detecting the vaccine effect, and has important value for developing and producing immunologic function detection kits for rabies virus vaccines.

We disclose Ebola Sudan Boniface virus GP Monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and / or therapeutic treatment of Ebola Sudan Boniface virus infections in vitro and in vivo.

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).

The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene.

The invention discloses a method for constructing virus live vector recombinant vaccine by utilizing transposon. Green fluorescent protein is taken as a report gene, expression boxes respectively expressing rabies virus glycoprotein and swine fever E2 protein genes are constructed and are cloned to the shuttle vector of the transposon, under the action of mediation of transposase, recombination with purified canine adenovirus type II virus and herpes virus type I entire genome are respectively carried out, then transfection agent (liposome and the like) is utilized to respectively transfect the recombination product with MDCK and Vero cells, thus obtaining four strains of recombinant viruses taking green fluorescent protein as report gene, namely recombinant canine adenovirus type II virus expressing glycoprotein, recombinant canine adenovirus type II virus expressing E2 protein, recombinant herpes virus type I expressing glycoprotein and recombinant herpes virus type I expressing E2 protein. Immunity test shows that the canine adenovirus type II virus expressing E2 gene and herpes virus type I live vector recombinant vaccine all can induce immunoreaction resistant to swine fever virus infection in swine and canine adenovirus type II virus expressing glycoprotein gene and herpes virus type I live vector recombinant vaccine all can induce immunoreaction resistant to rabies virus infection in dog.

This invention provides one glue gold test bar to test rabies virus protective antibody, which covers rabies virus protein and rabies multiple clone antibodies on the NC film and combines glue gold rabies virus antigen and applies film analysis double antigen clamper method and tests specimen rabies virus protective antibody.

Immunogenic compositions directed against Hendra and / or Nipah viruses, and methods of its use, are provided. In addition, methods of distinguishing subjects vaccinated with the immunogenic compositions of the invention from those infected with Hendra and / or Nipah virus are provided.

The invention discloses a neutralizing monoclonal antibody 3D8 identified HTNV-GP specific B cell epitope and key amino acid residue sequence of the epitope for treating hemorrhagic fever with renal syndrome (HFRS) caused by hantaan virus (HTNV) infection. The B cell epitope has an amino acid sequence of 882GFLCPEFPGSFRKKC896. The epitope peptide can be applied to study of mechanism of 3D8 neutralizing monoclonal antibody in treatment of HFRS, or preparation of drug for treating HFRS and preparation of novel vaccine strain aiming at hantaan virus 76-118, or development of novel diagnostic kitfor hantaan virus 76-118 as a target protein. The invention has good prospects of development and application in the field of HFRS specific immunotherapy.

The invention discloses a high immunogenicity rabies virus glycoprotein and its preparation method as well as application. The preparation method consists of: performing artificial synthesis to acquire an all dominant neutralization epitope-containing and codon optimized rabies virus glycoprotein gene, then taking a recombinant adenovirus, a recombinant baculovirus or a slow virus as an expression vector, and performing high-efficiency expression in a mammalian cell line, an insect cell line or a silkworm expression system, thus obtaining the rabies virus glycoprotein that has high immunogenicity to domestic epidemic rabies virus strains currently. And the high immunogenicity rabies virus glycoprotein is used for immunoprophylaxis of animal rabies.

The invention relates to a recombinant canine distemper virus capable of expressing a rabies virus glycoprotein (G protein). Specifically, the recombinant canine distemper virus is rCDV-RVG. The invention also discloses a method for preparing a vaccine strain from the recombinant canine distemper virus, and a use of the recombinant canine distemper virus in preparation of a bivalent vaccine for preventing rabies and canine distemper.